Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab

Published:2021-01-15 Issue:6 Volume:62 Page:1353-1360
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lyons Roger M.¹²,Shtivelband Mikhail³,Kingsley Edwin²³,Moezi Mehdi⁴,Richards Donald²⁵,Sharman Jeff²⁶,Feng Xiaoshu⁷,Cannan Megan⁷,Fellague-Chebra Rafik⁸,Boyd Thomas E.⁹

Affiliation:

1. Texas Oncology, San Antonio, TX, USA

2. US Oncology Research, The Woodlands, TX, USA

3. Ironwood Cancer and Research Center, Chandler, AZ, USA

4. Comprehensive Cancer Centers of Nevada, Las Vegas, NC, USA

5. Tyler Cancer Center, Tyler, TX, USA

6. Willamette Cancer Center, Eugene, OR, USA

7. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

8. Novartis Pharma S.A.S., Paris, France

9. Yakima Valley Memorial Hospital, Yakima, WI, USA

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1869957

Reference37 articles.

1. Targeting indolent non-Hodgkin lymphoma

2. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

4. First-line treatment of indolent lymphoma: axing CHOP?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3